Jane Plomley | White & Case LLP International Law Firm, Global Law Practice
Jane Plomley
Jane Plomley

Jane Plomley

Partner, Washington, DC

T +1 202 626 3708

T +1 202 626 3600

E jplomley@whitecase.com

in LinkedIn profile

Overview

Jane Plomley focuses on transactional work for major international pharmaceutical companies, biotech start-ups and individual inventors.

Her extensive knowledge of the pharmaceutical and biotechnology industries, combined with her thorough grasp of intellectual property law, enables her to offer clients in these sectors knowledgeable advice on a range of related matters.

Jane has many years' experience advising on IP licensing and commercial transactions, from major acquisitions, divestitures and collaboration agreements, to more operational arrangements such as supply agreements, contract research and clinical trial agreements.

Recent matters to which Jane has brought clarity and insight include a complex global agreement between two large pharmaceutical companies on a co-developed oncology drug, as well as various product acquisitions and divestures. She also recently advised on a collaboration agreement between two biotechnology companies.

Jane has been recognized as a leading licensing lawyer by various professional directories, and has been named as one the World's Leading Patent and Technology Licensing Lawyers by Intellectual Asset Magazine (IAM). Clients interviewed by IAM praised her "excellent" drafting skills, as well as her combination of "legal expertise" and "good business sense."

Prior to joining White & Case, Jane was a Senior Associate with a leading Australian law firm, where her practice focused on litigation, counseling and transactional matters involving pharmaceuticals, medical devices, foods, cosmetics and personal care products.

Dual-qualified in the United States and Australia, Jane is a member of a number of professional associations, including the Licensing Executives Society.

Bars and Courts

  • District of Columbia Bar
  • New York State Bar
  • New South Wales, Australia
  • High Court of Australia

Education

  • LLB, University of Sydney
  • BSc, University of Sydney

Languages

  • English

Experience

Acquisition of a controlling stake in Alvogen, 2015

Acquisition of a controlling stake in Alvogen, a leading generic pharmaceuticals company, by a consortium led by CVC Capital Partners.

Zimmer's acquisition of Biomet, 2014

Zimmer's acquisition of Biomet in a cash and equity transaction valued at approximately $14 billion, together with the related sales of Zimmer's U.S. ZUK unicondylar knee implant business to Smith & Nephew and of Biomet's U.S. Discovery Total Elbow implant business and Cobalt Bone Cement business to DJO Global, Inc.

Zimmer's acquisition of Biomet, 2014

Zimmer's acquisition of Biomet in a cash and equity transaction valued at approximately $14 billion, together with the related sales of Zimmer's U.S. ZUK unicondylar knee implant business to Smith & Nephew and of Biomet's U.S. Discovery Total Elbow implant business and Cobalt Bone Cement business to DJO Global, Inc.

Collaboration, license and supply agreements, 2014

Collaboration, license and supply agreements between a major pharmaceutical company and a leading UK gene and cell therapy company relating to certain platform technologies for use in T cell receptor therapy.

Agreement between two European pharmaceutical companies

Advised on an agreement between two large European pharmaceutical companies for the commercialization of an oncology drug which they had co-developed. The transaction involved the division of the global market into five regions, and the assignment to the two companies of different rights, regarding the drug's promotion and sale in each region.

Alliance between two pharmaceutical companies

Advised on a strategic alliance between two pharmaceutical companies for the co-promotion worldwide of a small molecule product in late-stage development.

Product acquisition in the pharmaceutical sector

Advised on the acquisition of a product licensed to a major pharmaceutical company, with regard to the restructuring of existing licensing and joint venture arrangements.

Product divestiture in the pharmaceutical sector

Advised on the divestiture of a mature product by one pharmaceutical company to another in the US, and related supply arrangements.

Product acquisition in the pharmaceutical sector

Advised on the acquisition of a pharmaceutical product in late-stage development, which needed to be divested as part of a high-profile merger.

Strategic alliance negotiation and restructuring

Advised on the negotiation and subsequent restructuring of a strategic alliance between a major pharmaceutical company and a small biotech start-up, with regard to the co-development and worldwide commercialization of three products in early-stage development.

Awards & Recognition

IAM Patent 1000 2013

The World's Leading Patent Practitioners—Recommended, Washington, DC, Metro Area

IAM Patent 1000 2012

The World's Leading Patent Practitioners

LMG Life Sciences 2012

Life Sciences Star